TVAX Biomedical
TVAX Biomedical is developing a paradigm-shifting cancer treatment that offers the opportunity for improved clinical outcomes and low toxicity, and the potential for fundamentally changing the way cancer is treated.
TVAX Biomedical is developing an exciting novel approach to cancer treatment (TVAX Immunotherapy®) that offers the promise of improved clinical outcomes for patients with any type of cancer, low toxicity and the potential for fundamentally changing the way cancer is treated.
TVAX Immunotherapy® is a unique personalized “killer” T cell treatment. TVAX Immunotherapy employs the natural ability of fully activated ‘killer’ T cells to kill cancer cells, including cancer stem cells. “Killer” T cells have demonstrated the ability to effectively treat numerous cancers without most of the undesirable side effects associated with radiation and chemotherapy. TVAX is distinct from other cancer immunotherapy companies in its use of ex vivo-activated cancer neoantigen-specific “killer” T cells obtained from patients vaccinated with their own cancer as the active agent in its treatment.
Pretreatment
Treatment
TVAX’s lead candidate (TVI-Brain-1) is currently being evaluated for the treatment of brain cancer, specifically glioblastoma. The United States Food and Drug Administration (FDA) granted the company Fast Track Designation for its pivotal Phase 2b trial for TVI-Brain-1, which is designed to support the therapy’s potential FDA approval. Additionally, the company received a $2 million grant from the FDA office of orphan products for this clinical trial.